Incorporate into pharmacological practice the latest clinical efficacy and safety data for new and emerging ALK, ROS1, and NTRK-targeted agents, especially in relation to treatment resistance and CNS metastases
Assess guideline recommendations for the implementation of pharmacy-guided strategies to treat patients with NSCLC using ALK, ROS1, or NTRK-targeted therapy based on molecular testing
Describe ways to optimize treatment efficacy and mitigate risks using adverse event management strategies